Global Health & Biotech Archives | Page 8 of 285 | Be Korea-savvy

Archive by category Global Health & Biotech

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Series A led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments NEW YORK, Oct. 08, 2025 (Korea Bizwire) – Nilo Therapeutics, a biotechnology company harnessing neural circuits to restore immune homeostasis in disease, launched today with a $101 million Series A financing led by [...]

Insight Timer Launches Free Therapist Hub to Support Mental Health Professionals

Insight Timer Launches Free Therapist Hub to Support Mental Health Professionals

In time for World Mental Health Day, Insight Timer’s Therapist Hub helps mental health professionals support clients, grow their practice, and care for their own well-being — all for free. SAN FRANCISCO, Oct. 08, 2025 (Korea Bizwire) – Insight Timer, the world’s largest mental health community with over 30 million members, today launched Therapist Hub, a free [...]

Philips announces 5,000th Zenition mobile C-arm system installation, advancing access to high-quality, efficient surgical and interventional care worldwide

Philips announces 5,000th Zenition mobile C-arm system installation, advancing access to high-quality, efficient surgical and interventional care worldwide

October 8, 2025 Global adoption milestone underscores innovation in mobile C-arm surgical and interventional imaging, with more than 15 million patients treated in 170+ countries every year Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the 5,000th installation of its Philips Zenition mobile surgery imaging system at [...]

Rentschler Biopharma further expands its services in Japan and South Korea and will attend BioProcess International Asia

Rentschler Biopharma further expands its services in Japan and South Korea and will attend BioProcess International Asia

Members of Management and Business Development will be at BioProcess International Asia in Kyoto, Japan, October 20-22, 2025 Company will introduce the Rentschler Expression Platform for accelerated timelines in Cell Line Development and Rentschler Development Services for best-fit solutions LAUPHEIM, Germany, Oct. 06, 2025 (Korea Bizwire) – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for [...]

FCTC’s Failure to Uphold Harm Reduction Risks Global Public Health

FCTC’s Failure to Uphold Harm Reduction Risks Global Public Health

MANILA, Philippines, Oct. 06, 2025 (Korea Bizwire) – The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) has serious concerns over how The World Health Organization’s Framework Convention on Tobacco Control (FCTC) defines tobacco control as including harm reduction, yet the current COP11 agenda dangerously ignores this core principle. Article 1(d) explicitly identifies harm reduction [...]

Moffitt Cancer Center Selects Evident’s Pramana Technology to Expand Digital Pathology

Moffitt Cancer Center Selects Evident’s Pramana Technology to Expand Digital Pathology

WALTHAM, Mass., Oct. 02, 2025 (Korea Bizwire) – Moffitt Cancer Center and Evident, which recently acquired Pramana Inc., today announced a strategic partnership, leveraging the Pramana high-throughput scanning system to support digital adoption across Moffitt’s clinical and research programs. “Digital pathology is critical to advancing precision oncology,” said Karen Lu, MD, Executive Vice President and Physician-in-Chief at [...]

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease

AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease

AAVB-039 addresses the root cause of the disease, benefitting patients with any ABCA4 mutation AAVB-039 is currently being assessed in the CELESTE interventional clinical trial and we continue recruiting in our STELLA observational study MILAN, Oct. 02, 2025 (Korea Bizwire) – AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced [...]

Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty

Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty

Completes the CORIOGRAPH Services portfolio which also includes solutions for knee and hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its CORIOGRAPH Pre-Op Planning and Modeling Services for total shoulder arthroplasty, now available in the United States. This innovative software offers image-based planning capabilities that enable surgeons to [...]

Carestream Introduces New Software Update to Boost Diagnostic Accuracy

Carestream Introduces New Software Update to Boost Diagnostic Accuracy

New Enhancements Elevate Confidence, Enhance Patient Care Rochester, N.Y., Oct. 01, 2025 (Korea Bizwire) – Carestream today announced the latest update to its Image Suite V4 Software, MR 11: a series of enhancements to help improve customer confidence and increase diagnostic accuracy while delivering a more user and patient-friendly experience.  Designed to optimize imaging performance [...]

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without background therapy versus placebo.1 Both FIBRONEER™ phase III trials, had met their primary endpoint (reduction of lung function decline measured in forced vital capacity) but [...]